PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Kappos, Ludwig
TI  - Results of DECIDE: DAC HYP Superior to IFN-β-1a for RRMS
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 15--16
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/15.short
4100  - http://mdc.sagepub.com/content/14/29/15.full
AB  - This article describes the results of the phase 3, randomized, double-blind, double-dummy, active-controlled Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis trial [DECIDE; NCT01064401] establishing the superiority of the humanized monoclonal antibody, daclizumab high-yield process (DAC HYP), to interferon beta-1a (IFN-β-1a) in the treatment of relapsing-remitting multiple sclerosis (RRMS).